A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis

European Radiology Experimental

Table 1 Baseline demographics and clinical characteristics of 29 patients who underwent DEB-TACE

Characteristics	Value
Sex
Male	24 (83)
Female	5 (17)
Age, mean ± SD (range), years	68 ± 8.0 (50–87)
Tumor size, median (IQR), cm	2.4 (1.4–3.5)
Number of tumors treated with DEB-TACE, per patient
One	16 (55)
Two	9 (31)
Three	4 (14)
AST, median (IQR), IU/L	42 (26–58)
ALT, median (IQR), IU/L	34 (21–47)
Total bilirubin, median (IQR), mg/dL	0.8 (0.5–1.1)
Albumin, mean ± SD, g/dL	3.9 ± 0.5
INR, median (IQR)	1.1 (0.9–1.3)
Child-Pugh grade, per patient
A	26 (90)
B	3 (10)
Catheter tip location during CTHA, per patient
Celiac trunk	9 (31)
Common hepatic artery	17 (59)
Proper hepatic artery	1 (3)
Others	2 (7)
Interval between DEB-TACE session and first follow-up imaging, median (IQR), weeks	6.7 (3.7−9.7)
Modality of imaging follow-up
CT	19 (66)
MRI	9 (31)
CT and MRI	1 (3)

Continuous data are expressed as mean ± standard deviation (SD) or median (IQR), categorical data as number of patients (percentage). ALT Alanine aminotransferase, AST Aspartate aminotransferase, CTHA Computed tomography during hepatic arteriography, DEB-TACE Drug-eluting beads transarterial chemoembolization, INR International normalized ratio, IQR Interquartile range, MRI Magnetic resonance imaging